News | September 07, 2010

Long-Term Data Supports Cypher Over Endeavor in High-Risk Subgroups

September 7, 2010 – New analyses of subgroups from the SORT OUT III study provide detail on longer-term follow-up safety and efficacy outcomes in diabetics and patients with acute coronary syndrome and multiple lesions.Three new analyses of subgroups were presented at the European Society of Cardiology (ESC) meeting last week in Stockholm. These important data add detail to those already published in the March 2010 issue of The Lancet on the clinical outcomes for the primary endpoint in the total population and in multiple subgroups at nine months followup and on clinical outcomes at 18-month followup of the randomized comparison of the Cypher stent and the Endeavor stent.

The initial results of the SORT OUT III study showed significantly reduced adverse events at nine and 18 months for the Cypher sirolimus-eluting coronary stent over Medtronic's Endeavor zotarolimus-eluting stent in an unselected group of 2,332 patients undergoing coronary intervention in real-world clinical practice. The authors reported that subgroup analysis of the primary endpoint of nine-month major adverse cardiac events (MACE, defined as a composite of cardiac death, myocardial infarction [MI] or target vessel revascularization [TVR]) were also consistent across all subgroups.

The new data from ESC provide important additional information on longer-term outcomes at 18 months in three key groups of patients that are at higher risk of adverse events when undergoing coronary intervention, namely patients with diabetes, acute coronary syndromes and treatment of multiple lesions. These data confirm that the significant reductions in major adverse events in these subgroups seen at nine months with the Cypher compared to the Endeavor were sustained through 18 months of followup and provide important details of how the components of MACE contribute to the reduction in major adverse events.

Diabetics
Among the high-risk diabetic patient population in SORT OUT III, the incidence of MACE at 18 months was significantly reduced by 74 percent with Cypher vs. Endeavor (4.8 percent in the Cypher group vs. 18.3 percent in the Endeavor group; hazard ratio 4.05; 95 percent confidence intervals: 1.86-8.82). This difference was driven by statistically significant reductions in death, MI, TVR and TLR favoring the Cypher stent. In the Cypher group, the incidence of MACE was also significantly reduced by 46 percent compared to the Endeavor in patients without diabetes (4.5 percent in the Cypher group vs. 8.3 percent in the Endeavor group; hazard ratio 1.87, 95 percent confidence intervals: 1.30-2.69).

Coronary Syndromes
Among patients with acute coronary syndrome in SORT OUT III (defined as patients with unstable angina or myocardial infarction), the incidence of MACE at 18 months was reduced by 43 percent with Cypher vs. Endeavor (5 percent in the Cypher group vs. 8.7 percent in the Endeavor group; hazard ratio 1.78; 95 percent confidence intervals: 1.10-2.88). This difference was driven by a statistically significant reduction in TLR and TVR favoring the Cypher. In the Cypher group the incidence of MACE also was reduced by 60 percent compared to the Endeavor stent in patients with stable angina (4.2 percent in the Cypher group vs. 10.4 percent in the Endeavor group; hazard ratio 2.53, 95 percent confidence intervals: 1.60-4.02).

Multiple Lesions
Among the high-risk group treated for disease in multiple lesions in SORT OUT III, the incidence of MACE at 18 months was reduced by 80 percent with Cypher vs. Endeavor (2.6 percent in the Cypher group vs. 13.2 percent in the Endeavor group; hazard ratio 5.29; 95 percent confidence intervals: 2.59-10.8). This difference was driven by statistically significant reductions in death, MI and TVR favoring Cypher. In the Cypher group the incidence of MACE was also significantly reduced by 35 percent compared to the Endeavor in patients treated for disease in one lesion (5.4 percent in the Cypher group vs. 8.3 percent in the Endeavor group).

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init